Topical microbicides for the prevention of genital herpes infection

Marla J. Keller, Ana Tuyama, Maria Josefina Carlucci, Betsy Herold

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Genital herpes is one of the most prevalent sexually transmitted infections worldwide and is the most common cause of genital ulcers. Despite increased public awareness and the initiation of efforts to prevent transmission, the prevalence of herpes simplex virus (HSV) type 2 continues to increase. What makes HSV so difficult to control is that most sexual and perinatal transmission occurs during unrecognized or asymptomatic shedding. The impact of genital herpes as a public health threat is amplified because of its epidemiological synergy with HIV/AIDS. Thus, there is an urgent need for novel prophylactic methods, such as topical microbicides designed for genital application, to prevent both HSV and HIV transmission. Several candidate microbicides are being advanced to clinical trials based on in vitro activity and animal studies. These include compounds that inactivate virus directly, those that enhance innate immunity, and drugs that block viral binding and entry. A more vigorous evaluation of the safety of these and other candidate topical microbicides in development should include assessment of the impact of repeated application on innate host defences in the genital tract.

Original languageEnglish (US)
Pages (from-to)420-423
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Volume55
Issue number4
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Herpes Genitalis
Local Anti-Infective Agents
Simplexvirus
HIV
Human Herpesvirus 2
Sexually Transmitted Diseases
Anti-Infective Agents
Infection
Innate Immunity
Ulcer
Acquired Immunodeficiency Syndrome
Public Health
Clinical Trials
Viruses
Safety
Pharmaceutical Preparations
In Vitro Techniques

Keywords

  • HIV
  • HSV
  • Innate immunity

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology

Cite this

Topical microbicides for the prevention of genital herpes infection. / Keller, Marla J.; Tuyama, Ana; Carlucci, Maria Josefina; Herold, Betsy.

In: Journal of Antimicrobial Chemotherapy, Vol. 55, No. 4, 04.2005, p. 420-423.

Research output: Contribution to journalArticle

@article{1aa553d5d44141d28782906076dcacb8,
title = "Topical microbicides for the prevention of genital herpes infection",
abstract = "Genital herpes is one of the most prevalent sexually transmitted infections worldwide and is the most common cause of genital ulcers. Despite increased public awareness and the initiation of efforts to prevent transmission, the prevalence of herpes simplex virus (HSV) type 2 continues to increase. What makes HSV so difficult to control is that most sexual and perinatal transmission occurs during unrecognized or asymptomatic shedding. The impact of genital herpes as a public health threat is amplified because of its epidemiological synergy with HIV/AIDS. Thus, there is an urgent need for novel prophylactic methods, such as topical microbicides designed for genital application, to prevent both HSV and HIV transmission. Several candidate microbicides are being advanced to clinical trials based on in vitro activity and animal studies. These include compounds that inactivate virus directly, those that enhance innate immunity, and drugs that block viral binding and entry. A more vigorous evaluation of the safety of these and other candidate topical microbicides in development should include assessment of the impact of repeated application on innate host defences in the genital tract.",
keywords = "HIV, HSV, Innate immunity",
author = "Keller, {Marla J.} and Ana Tuyama and Carlucci, {Maria Josefina} and Betsy Herold",
year = "2005",
month = "4",
doi = "10.1093/jac/dki056",
language = "English (US)",
volume = "55",
pages = "420--423",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Topical microbicides for the prevention of genital herpes infection

AU - Keller, Marla J.

AU - Tuyama, Ana

AU - Carlucci, Maria Josefina

AU - Herold, Betsy

PY - 2005/4

Y1 - 2005/4

N2 - Genital herpes is one of the most prevalent sexually transmitted infections worldwide and is the most common cause of genital ulcers. Despite increased public awareness and the initiation of efforts to prevent transmission, the prevalence of herpes simplex virus (HSV) type 2 continues to increase. What makes HSV so difficult to control is that most sexual and perinatal transmission occurs during unrecognized or asymptomatic shedding. The impact of genital herpes as a public health threat is amplified because of its epidemiological synergy with HIV/AIDS. Thus, there is an urgent need for novel prophylactic methods, such as topical microbicides designed for genital application, to prevent both HSV and HIV transmission. Several candidate microbicides are being advanced to clinical trials based on in vitro activity and animal studies. These include compounds that inactivate virus directly, those that enhance innate immunity, and drugs that block viral binding and entry. A more vigorous evaluation of the safety of these and other candidate topical microbicides in development should include assessment of the impact of repeated application on innate host defences in the genital tract.

AB - Genital herpes is one of the most prevalent sexually transmitted infections worldwide and is the most common cause of genital ulcers. Despite increased public awareness and the initiation of efforts to prevent transmission, the prevalence of herpes simplex virus (HSV) type 2 continues to increase. What makes HSV so difficult to control is that most sexual and perinatal transmission occurs during unrecognized or asymptomatic shedding. The impact of genital herpes as a public health threat is amplified because of its epidemiological synergy with HIV/AIDS. Thus, there is an urgent need for novel prophylactic methods, such as topical microbicides designed for genital application, to prevent both HSV and HIV transmission. Several candidate microbicides are being advanced to clinical trials based on in vitro activity and animal studies. These include compounds that inactivate virus directly, those that enhance innate immunity, and drugs that block viral binding and entry. A more vigorous evaluation of the safety of these and other candidate topical microbicides in development should include assessment of the impact of repeated application on innate host defences in the genital tract.

KW - HIV

KW - HSV

KW - Innate immunity

UR - http://www.scopus.com/inward/record.url?scp=17444386394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444386394&partnerID=8YFLogxK

U2 - 10.1093/jac/dki056

DO - 10.1093/jac/dki056

M3 - Article

C2 - 15743896

AN - SCOPUS:17444386394

VL - 55

SP - 420

EP - 423

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 4

ER -